Which adults with ulcerative colitis or Crohn’s disease is Entyvio (vedolizumab) indicated to treat?

Entyvio (vedolizumab) is indicated for adults with moderately to severely active ulcerative colitis or Crohn’s disease who have had an inadequate response to, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF-alpha) antagonist.